PDE4 inhibitor Roflumilast is FDA-approved for treating severe chronic obstructive pulmonary disease (COPD) [25], but the specific role of PDE10A in NLRP3 inflammasome activation remains unclear. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.